OncoSec purchases Phesi ClinSite licence for immune-oncology trials

23rd January 2020 (Last Updated January 23rd, 2020 15:07)

OncoSec Medical has secured a multi-year ClinSite licence from clinical development analytics products and services provider Phesi.

OncoSec Medical has secured a multi-year ClinSite licence from clinical development analytics products and services provider Phesi.

ClinSite is a self-service, artificial intelligence (AI)-powered tool enabling biopharmaceutical companies to search for top-performing investigator sites to conduct clinical trials across all therapeutic areas.

The software as a service (SaaS) solution incorporates natural language processing and machine learning capabilities. In July last year, Phesi launched ClinSite tool.

OncoSec noted that ClinSite will enable planning for Phase II and III clinical trials of anticancer immunotherapies developed using OncoSec’s plasmid deoxyribonucleic acid (DNA) delivery platform.

Phesi founder and president Gen Li said: “As a ClinSite licencee, OncoSec can utilise this novel tool to select the right investigator sites for their immune-oncology clinical trials across a range of tumour types.

“Many drug studies fail or are unnecessarily prolonged due to the lack of timely and precise data to inform trial protocols and investigator site selection. With our AI-driven predictive analytics and insights, Phesi’s tools generate accurate, real-time data, allowing companies such as OncoSec to accelerate their trial timelines and enhance their efficiency.”

The ClinSite platform includes data from 4.2 million physicians and nearly 600,000 investigator sites, identified from over 80,000 sources and 330,000 clinical trials across 240 countries.

Investigator sites selected through the ClinSite platform in more than 250 clinical trials have enrolled participants up to 40% faster than other locations.

OncoSec chief clinical development officer Kellie Malloy Foerter said: “Access to Phesi’s innovative technology will be a boon to OncoSec’s clinical development programs, particularly our later-stage trials in advanced melanoma, head and neck cancer, and triple-negative breast cancer.

“Despite the relatively small patient populations affected by these malignancies, the array of unmet medical needs, combined with the sheer number of ongoing and planned clinical trials in these indications, presents a complex landscape for patients, investigators, and trial sponsors to negotiate.”